The Global Use of Medicines - IMS Health

KEY DRIVERS OF CHANGE
In pharmerging markets growth is mostly from generic drugs
In pharmerging markets growth is mostly from generic drugs
2010
2010
Growth
to
Growth
2015
to 2015
Source: IMS Market Prognosis, Apr 2011
Pharmerging Spending and Growth
Pharmerging Spending and Growth
China Brazil India Russia
China Brazil India Russia
41.1
41.1
6.7
6.7
62.6
62.6
10.2
10.2
22.9
22.9
16.8
1.6
12.3
6.5 2.8
13.4 11.0
3.0
Source: IMS Market Prognosis, Apr 2011
12.3
6.5 2.8
16.8
1.6
13.6
4.8
13.4 11.0
3.0
3.9
13.6
4.8
3.9
Tier 3
Pharmerging
Tier 3
Pharmerging
60.6
25.1
45.7
14.0
60.6
25.1
45.7
14.0
Total spending
Total Brand spending
Brand spending
•! Pharmerging countries are expected to ne
• double Pharmerging pharmaceutical countries are spending expected toin the nex
five nearly years, double adding pharmaceutical $150Bn spending, over that period
adding $150Bn by 2015. Of the total
•! Of the total increase in spending,
increase in spending, approximately 20%
approximately 20% will come from brande
will come from branded products.
products.
• Many of the pharmerging countries have
•! Many strong of domestic the Pharmerging companies which countries markethave
strong low cost domestic generics, branded companies generics, which andmarket
cost in some generics, cases, unauthorized branded generics, copies of and in so
cases, original unauthorized brands. copies of original bran
•! • Political pressure to to provide provide greater greater access access
healthcare to is is driving significant governmen
government-supported expansion expansion of access ofto medicine
across access to these medicines countries. across these countries.
•! • Patients pay pay for for the the majority majority of medicines of medicines
out-of-pocket in in these these markets, markets, with with a a few
exceptions, few exceptions, which which limits limits the the usage of of
expensive newer newer medicines. medicines.
Chart notes
Spending share in US$ with variable exchange rates.
Chart Notes:
Spending Growth share in US$ in at US$ constant with exchange variable rates. exchange rates.
Growth Gross in Domestic US$ at Product constant (GDP) exchange from the rates. Economist
Gross Intelligence Domestic Unit. Product (GDP) from the Economist Intelligence
Unit.
Brands include vaccines, but exclude branded generics,
Brands include vaccines using IMS’s proprietary market
using IMS MIDAS market segmentation methodology.
segmentation methodology.
The Global Use of Medicines: Outlook Through 2015
The Global Report Use by of the Medicines: IMS Institute Outlook for Through Healthcare 2015 Informatics
Report by the IMS Institute for Healthcare Informatics
12
1